The company will market its Deep TMS device for the treatment of Parkinson's disease and as an add-on therapy for depression.
Brainsway Ltd. (TASE:BRIN) has received EU CE Mark certification to market its Deep TMS (transcranial magnetic stimulation) non-invasive device for the treatment of Parkinson's disease and as an add-on therapy for depression in Europe.
Brainsway's share price rose 2.7% in morning trading to NIS 9.10, giving a market cap of NIS 421 million.
Published by Globes [online], Israel business news - www.globes-online.com - on April 3, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011